RELAPSED AND REFRACTORY MM PROGRESSING ON 2L

Is SARCLISA + Pd appropriate for your RRMM patients?

Meet Ben – A patient with relapsed and refractory MM with disease progression on 2L treatment

Age
70 years old
Gender
Male
Time since MM diagnosis
5.5 years
R-ISS stage at diagnosis
Stage I
Additional medical history
Former smoker

Initial treatment

  • Induction therapy was initiated with the bortezomib, thalidomide, dexamethasone (VTd) regimen
  • Ben achieved a sCR and received ASCT

Disease progression

  • Ben’s disease progressed 3.5 years after ASCT
  • Ben received second-line treatment with the lenalidomide, dexamethasone (Rd) regimen and achieved a VGPR
  • Two years later, Ben was diagnosed with disease progression after a regular follow-up with his doctor

Additional patient information

Cytogenetic risk
Standard
Bone marrow plasma cells
50%
Hg
10 g/dL
Renal function (CrCl)
80 mL/min/1.73 m2
Would Ben be a candidate for treatment with SARCLISA + Pd?

Ben would be suitable for treatment with SARCLISA + Pd1,2

This patient profile does not meet the criteria for use to receive SARCLISA + Pd via the Cancer Drugs Fund. Reimbursement is available at 4L treatment only.*

Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2

You are now leaving the https://sarclisa.co.uk website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.

CONTINUE